antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2020-65-1-2-44-53antibiotics-709Research ArticleОБЗОРЫREVIEWSВоздействие полисахаридов из морских водорослей на патогенетические мишени Helicobacter pylori - новое направление в терапии и профилактике хеликобактерной инфекцииThe Influence of Polysaccharides from Sea Algae on the Pathogenetic Targets of Helicobacter Pylori — a New Direction in Therapy and Prevention of InfectionБеседноваН. Н.BesednovaN. N.

Владивосток

Vladivostok

КузнецоваТ. А.KuznetsovaT. A.

Владивосток

Vladivostok

takuznets@mail.ruЗапорожецТ. С.ZaporozhetsT. S.

Владивосток

Vladivostok

КрыжановскийС. П.KryzhanovskyS. P.

Владивосток

Vladivostok

ГажаА. К.GazhaA. K.

Владивосток

Vladivostok

ДобряковЕ. Ю.DobryakovE. Yu.

Владивосток

Vladivostok

ЗвягинцеваТ. Н.ZvyagintsevaT. N.

Владивосток

Vladivostok

Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. СомоваРоссияSomov Institute of Epidemiology and MicrobiologyRussian FederationДальневосточный Федеральный УниверситетРоссияFar Eastern Federal UniversityRussian FederationМедицинское объединение ДВО РАНРоссияMedical Association of the Far Eastern Branch of the Russian Academy of SciencesRussian FederationТихоокеанский институт биоорганической химии им. Г.Б.Елякова ДВО РАНРоссияG. B. Elyakov Pacific Institute of Bioorganic ChemistryRussian Federation202025052020651-24453Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/709

Согласно эпидемиологическим данным, инфицированность Helicobacter pylori составляет около 60% населения планеты. Применяемое многокомпонентное лечение в 18-20% случаев не позволяет добиться эрадикации H.pylori. Кроме того у большинства пролеченных пациентов через 3-5 лет наступает реинфекция H.pylori. Альтернативой антибиотикам при лечении этой инфекции являются продукты из морских водорослей, в частности экстракты и полисахариды, обладающие антиадгезивными, антитоксическими, иммуномодулирующими, антиоксидантными и противовоспалительными свойствами. Кроме того, полисахариды водорослей оказытают прямое бактерицидное действие и могут разрушать биоплёнки, образованные H.pylori. Представленные в обзоре литературы современные материалы свидетельствуют о перспективности разработок, связанных с использованием экстрактов и полисахаридов из морских водорослей в качестве основы лекарственных препаратов, БАД к пище и продуктов функционального питания для профилактики и лечения хеликобактерной инфекции.

According to epidemiological data, 60% of the world's population suffers from Helicobacter pyloriinfection. The multicomponent treatment used in 18–20% of cases does not allow eradication of H.pylori. In addition, reinfection with H.pylori occurs in the majority of treated patients in 3–5 years. An alternative to antibiotics in the treatment of this infection are seaweed products, in particular extracts and polysaccharides with anti-adhesive, anti-toxic, immunomodulatory, antioxidant, and anti-inflammatory properties. Furthermore, algae polysaccharides have direct bactericidal effect and can destroy biofilms formed by H.pylori. The modern materials presented in the literature review indicate the prospects of developments related to the use of extracts and polysaccharides from seaweed as the basis for drugs, dietary supplements and functional food products for the prevention and treatment of H.pylori infection.

морские водорослиполисахаридыинфекция Helicobacter pyloriпатогенетические мишенигастроэнтерологияseaweedpolysaccharidesHelicobacter pylori infectionpathogenetic targetsgastroenterologyReferencesMarshall B.J., Warren L.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1 (8390): 1311–1315.Marshall B.J., Warren L.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1 (8390): 1311–1315.Kao C.Y., Chen J.W., Huang Y.T., Sheu S.M., Sheu B.S., Wu J.J. Genome sequence and annotation of Helicobacter pylori strain Hp238, isolated from a Taiwanese patient with mucosa-associated lymphoid tissue lymphoma. Genome Announc 2015; 3 (1): e00006-15.Kao C.Y., Chen J.W., Huang Y.T., Sheu S.M., Sheu B.S., Wu J.J. Genome sequence and annotation of Helicobacter pylori strain Hp238, isolated from a Taiwanese patient with mucosa-associated lymphoid tissue lymphoma. Genome Announc 2015; 3 (1): e00006-15.Wang F., Meng W., Wang B., Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345 (2): 196–202.Wang F., Meng W., Wang B., Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345 (2): 196–202.Menchicchi B., Hensel A., Goycoolea F.M. Polysaccharides as bacterial antiadhesive agents and «smart» constituents for improved drug delivery systems against Helicobacter pylori infection. Curr Pharm Des 2015; 21 (33): 4888–4906.Menchicchi B., Hensel A., Goycoolea F.M. Polysaccharides as bacterial antiadhesive agents and «smart» constituents for improved drug delivery systems against Helicobacter pylori infection. Curr Pharm Des 2015; 21 (33): 4888–4906.Ярмолик E.C. Роль хеликобактерной инфекции в развитии хронических кожных заболеваний. Журн Гродненского гос мед университета. - 2012. - № 4. - С. 18-22.Yarmolik E.S. Rol' khelikobakternoj infektsii v razvitii khronicheskikh kozhnykh zabolevanij. Zhurn Grodnenskogo gos med universiteta 2012; 4: 18–22. [in Russian]Ахмедов B.A., Гауе O.B. Внежелудочные проявления, ассоциированные с инфекцией Helicobacter pylori. Клин мед. - 2017. - № 95 (1). - С. 15-22.Akhmedov V.A., Gaus O.V. Vnezheludochnye proyavleniya, assotsiirovannye s infektsiej Helicobacter pylori. Klin med 2017; 95 (1): 15–22. [in Russian]Cammarota G., Sanguinetti M., Gallo A., Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012; 36 (3): 222–230.Cammarota G., Sanguinetti M., Gallo A., Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012; 36 (3): 222–230.Shibata H., Imuro M., Uchiya N., Kawamori T., Nagaoka M., Ueyama S. et al. Preventive effects of Cladosiphon fucoidan against H. pylori infection in Mongolian gerbils. Helicobacter 2003; 8 (1): 59–65.Shibata H., Imuro M., Uchiya N., Kawamori T., Nagaoka M., Ueyama S. et al. Preventive effects of Cladosiphon fucoidan against H.pylori infection in Mongolian gerbils. Helicobacter 2003; 8 (1): 59–65.Fitton J.H., Stringer D.N., Park A.Y., Karpiniec S.S. Therapies from fucoidan: new developments. Mar Drugs 2019; 17 (10): 571.Fitton J.H., Stringer D.N., Park A.Y., Karpiniec S.S. Therapies from fucoidan: new developments. Mar Drugs 2019; 17 (10): 571.Ofec I., Hasty D.L., Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 2003; 38 (3): 181–191.Ofec I., Hasty D.L., Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 2003; 38 (3): 181–191.Menshova R.V., Shevchenko N.M., Imbs T.I., Zvyagintseva T.N., Maluarenko O.S., Zaporoshets T.S. et al. Fucoidans from brown alga Fucus evanescens: structure and biological activity. Front Mar Sci 2016; 3: 129.Menshova R.V., Shevchenko N.M., Imbs T.I., Zvyagintseva T.N., Maluarenko O.S., Zaporoshets T.S. et al. Fucoidans from brown alga Fucus evanescens: structure and biological activity. Front Mar Sci 2016; 3: 129.Delahay R.M., Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17: 9–15.Delahay R.M., Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17: 9–15.Поздеев O.K., Поздеева A.O., Валеева Ю.В., Гуляев П.Е. Механизмы взаимодействия H. pylori с эпителием слизистой оболочки желудка. Факторы патогенности, способствующие успешной колонизации. Инфекция и иммунитет. - 2018. - № 8 (3). - С. 273-283.Pozdeev O.K., Pozdeeva A.O., Valeeva Jyu.V., Gulyaev P.E. Mekhanizmy vzaimodejstviya H.pylori s epiteliem slizistoj obolochki zheludka. Faktory patogennosti, sposobstvujyushchie uspeshnoj kolonizatsii. Infektsiya i immunitet 2018; 8 (3): 273–283. [in Russian]Clyne M., Dolan B., Reeves E.P. Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Lett 2007; 268: 135–143.Clyne M., Dolan B., Reeves E.P. Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Lett 2007; 268: 135–143.Иеаева Г. Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori. Клин микробиол антимикроб химиотер. - 2018. Т 20. - № 1. - С. 14-23.Isaeva G. Sh., Valieva R.I. Biologicheskie svojstva i virulentnost' Helicobacter pylori. Klin Mikrobiol Antimikrob Khimioter 2018; 20 (1): 14–23. [in Russian]Koch K.S., Leffert H.L. Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010; 2010 (2): 39–47.Koch K.S., Leffert H.L. Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010; 2010 (2): 39–47.Mascellino M.T., Margani M., Oliva A. Helicobacter pylori: determinant and markers of virulence. Dis Markers 2009; 27 (3): 137–156.Mascellino M.T., Margani M., Oliva A. Helicobacter pylori: determinant and markers of virulence. Dis Markers 2009; 27 (3): 137–156.Успенский Ю.П., Горбачева И.А., Суворов A.H., Галагудза М.М., Барышникова Н.В., Богданова С.А. Иммунологические изменения при инвазии Helicobacter pylori: перспективы создания вакцин. Трансляционная мед. - 2018. - Т. 5. - № 6. - С. 31-40.Uspenskij Jyu.P., Gorbacheva I.A., Suvorov A.N., Galagudza M.M., Baryshnikova N.V., Bogdanova S.A. Immunologicheskie izmeneniya pri invazii Helicobacter pylori: perspektivy sozdaniya vaktsin. Translyatsionnaya Med 2018; 5 (6): 31–40. [in Russian]Ayala G., Cruz-Herrera C.F. Romero I. Exploring alternative treatments for H.pylori infection. World J Gastroenterol 2014; 20 (6): 1450–1469.Ayala G., Cruz-Herrera C.F. Romero I. Exploring alternative treatments for H.pylori infection. World J Gastroenterol 2014; 20 (6): 1450–1469.Kawakubo M., Ito Y., Okimura Y., Kobayashi M., Sakura K., Kasama S. et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305 (5686): 1003–1006.Kawakubo M., Ito Y., Okimura Y., Kobayashi M., Sakura K., Kasama S. et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305 (5686): 1003–1006.Huang Y., Wang Q.L., Cheng D.D., Xu W.T., Lu N.H. Adhesion and invasion of gastric mucosa epithelial cells by Helicobacter pylori. Front Cell Infect Microbiol 2016; 6: 159.Huang Y., Wang Q.L., Cheng D.D., Xu W.T., Lu N.H. Adhesion and invasion of gastric mucosa epithelial cells by Helicobacter pylori. Front Cell Infect Microbiol 2016; 6: 159.Foegeding N.J, Caston R.R., McClain M.S., Ohi M.D., Cover T.L. An overview of Helicobacter pylori VacA toxin biology. Toxins (Basel) 2016; 8 (6): e173.Foegeding N.J, Caston R.R., McClain M.S., Ohi M.D., Cover T.L. An overview of Helicobacter pylori VacA toxin biology. Toxins (Basel) 2016; 8 (6): e173.Terebiznic M.R., Vazquez C.L., Torbick K., Banks D., Wang T., Hong W. et al. Helicobacter pylori VacA toxin promotes bacterial intracellular survival in gastric epithelial cells. Infect. Immun 2006; 74 (12): 6599–6614.Terebiznic M.R., Vazquez C.L., Torbick K., Banks D., Wang T., Hong W. et al. Helicobacter pylori VacA toxin promotes bacterial intracellular survival in gastric epithelial cells. Infect. Immun 2006; 74 (12): 6599–6614.Chauhan N., Tay A.C.Y., Marshall B.J., Jain U. Helicobacter pylori VacA, a distinct toxin exert diverse functionalitics in numerous cells: an overview. Helicobacter 2019; 24 (1): e12544.Chauhan N., Tay A.C.Y., Marshall B.J., Jain U. Helicobacter pylori VacA, a distinct toxin exert diverse functionalitics in numerous cells: an overview. Helicobacter 2019; 24 (1): e12544.Агеева E.C., Иптышев B.M., Саранчина Ю.В., Штыгашева O.B. Роль апоптоза лимфоцитов крови в дизрегуляции иммунного ответа у пациентов с атрофическнм гастритом. Забайкальский мед вестник. - 2014. - № 3. - С. 94-98.Ageeva E.S., Iptyshev V.M., Saranchina Jyu.V., Shtygasheva O.V. Rol' apoptoza limfotsitov krovi v dizregulyatsii immunnogo otveta u patsientov s atroficheskim gastritom. Zabajkal'skij med vestnik 2014; 3: 94–98.Hathroubi S., Servetas S.L., Windham I., Merrell D.S., Ottemann K.M. Helicobacter pylori formation at its potential role in pathogenesis. Microbiol Mol Biol Rev 2018; 82 (2): e00001-18.Hathroubi S., Servetas S.L., Windham I., Merrell D.S., Ottemann K.M. Helicobacter pylori formation at its potential role in pathogenesis. Microbiol Mol Biol Rev 2018; 82 (2): e00001-18.Coticchia J.M., Sugawa C., Tran V.R., Gurrola J., Kowalski E., Carron M.A. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. J Gastrointest Surg 2006; 10 (6): 883–889.Coticchia J.M., Sugawa C., Tran V.R., Gurrola J., Kowalski E., Carron M.A. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. J Gastrointest Surg 2006; 10 (6): 883–889.Oleastro M., Menard A. The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology (Basel) 2013; 2 (3): 1110–1134.Oleastro M., Menard A. The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology (Basel) 2013; 2 (3): 1110–1134.Shibata H., Kimura-Takagi I., Nagaoka M., Hashimoto S., Sawada H., Ueyama S. et al. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. J Nutr Sci Vitaminol 1999; 45 (3): 325–336.Shibata H., Kimura-Takagi I., Nagaoka M., Hashimoto S., Sawada H., Ueyama S. et al. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. J Nutr Sci Vitaminol 1999; 45 (3): 325–336.Lutau N., Nilsson I., Wadstrom T., Ljungh A. Effect of heparin, fucoidan and other polysaccharides on adhesion of enterohepatic Helicobacter species to murine macrophages. Appl Biochem Biotechnol 2010; 19: 1–18.Lutau N., Nilsson I., Wadstrom T., Ljungh A. Effect of heparin, fucoidan and other polysaccharides on adhesion of enterohepatic Helicobacter species to murine macrophages. Appl Biochem Biotechnol 2010; 19: 1–18.Chua E.G., Verbrugghe P., Perkins T.T., Tay C.Y. Fucoidans disrupt adherence of H.pylori to AGS cells in vitro. Evid Based Complement Alternat Med 2015; 2015: 120981.Chua E.G., Verbrugghe P., Perkins T.T., Tay C.Y. Fucoidans disrupt adherence of H.pylori to AGS cells in vitro. Evid Based Complement Alternat Med 2015; 2015: 120981.Nagaoka M., Shibata H., Takagi I., Aiyama R., Hashimoto S. Effect of fucoidan from Cladosiphon okamuranus (Okinawa Mozuku) on the eradication of Helicobacter pylori. Cell (Tokyo) 2005; 37: 10: 30–33.Nagaoka M., Shibata H., Takagi I., Aiyama R., Hashimoto S. Effect of fucoidan from Cladosiphon okamuranus (Okinawa Mozuku) on the eradication of Helicobacter pylori. Cell (Tokyo) 2005; 37: 10: 30–33.Loke M.F., Lui S.Y., Ng B.L., Gong M., Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol 2007; 50 (2): 231–238.Loke M.F., Lui S.Y., Ng B.L., Gong M., Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol 2007; 50 (2): 231–238.Krylov V.B., Ustyjuzhanina N.E., Grachev A.A., Nifantiev N.E. Synthesis of large fucoidan fragments, potential inhibitors of microbial adhesion. 4th Baltte Meeting on Microbial Carbohydrates. 2010 Sept 19–22; Hyytiala, Finland. 50.Krylov V.B., Ustyjuzhanina N.E., Grachev A.A., Nifantiev N.E. Synthesis of large fucoidan fragments, potential inhibitors of microbial adhesion. 4th Baltte Meeting on Microbial Carbohydrates. 2010 Sept 19–22; Hyytiala, Finland. 50.Back H.I., Kim S.Y., Park S.H., Oh M.R., Kim M.G., Jeon J.Y. et al. Effects of fucoidan supplementation on Helicobacter pylori in humans. FASEB J 2010; 24: 1: Suppl Ib 347.Back H.I., Kim S.Y., Park S.H., Oh M.R., Kim M.G., Jeon J.Y. et al. Effects of fucoidan supplementation on Helicobacter pylori in humans. FASEB J 2010; 24: 1: Suppl Ib 347.Kim T.S., Choi E.K., Kim J., Shin K., Lee S.P., Choi Y. et al. Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans. Lab Anim Res 2014; 30 (3): 131–135.Kim T.S., Choi E.K., Kim J., Shin K., Lee S.P., Choi Y. et al. Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans. Lab Anim Res 2014; 30 (3): 131–135.Kim T.S., Shin K., Jeon J.H., Choi E.K., Choi Y., Lee S.P. et al. Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans. Lab Anim Res 2015; 31 (1): 7–12.Kim T.S., Shin K., Jeon J.H., Choi E.K., Choi Y., Lee S.P. et al. Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans. Lab Anim Res 2015; 31 (1): 7–12.Cai J., Kim T.S., Jang J.Y., Kim J., Shin K., Lee S.P. et al. In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract. Lab Anim Res 2014; 30 (1): 28–34.Cai J., Kim T.S., Jang J.Y., Kim J., Shin K., Lee S.P. et al. In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract. Lab Anim Res 2014; 30 (1): 28–34.Funatogawa K., Hayashi S., Shimomura H., Yoshida T., Hatano T., Ito H. et al. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol Immunol 2004; 48 (4): 251–261.Funatogawa K., Hayashi S., Shimomura H., Yoshida T., Hatano T., Ito H. et al. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol Immunol 2004; 48 (4): 251–261.Решетников О.В., Курилович C.A., Кротов C.A., Белковец Ф.В. Физиологическое и клиническое значение пепсиногенов желудка. Клин мед. - 2014. - № 3. - С. 26-30.Reshetnikov O.V., Kurilovich S.A., Krotov S.A., Belkovets F.V. Fiziologicheskoe i klinicheskoe znachenie pepsinogenov zheludka. Klin med 2014; 3: 26–30. [in Russian]Massarrat S., Haj-Sheykholeslami A., Mohamadkhani A., Zendehdel N., Aliasgari A., Rakhshani N. et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H.pylori eradication. Biomed Res Int 2014; 2014: 481607.Massarrat S., Haj-Sheykholeslami A., Mohamadkhani A., Zendehdel N., Aliasgari A., Rakhshani N. et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H.pylori eradication. Biomed Res Int 2014; 2014: 481607.Choi H.S., Lee S.Y., Kim J.H., Sung I.K., Park H.S., Shim C.S. et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis 2014; 15 (6): 293–298.Choi H.S., Lee S.Y., Kim J.H., Sung I.K., Park H.S., Shim C.S. et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis 2014; 15 (6): 293–298.Fitton J.H., Stringer D.N., Karpiniec S.S. Therapies from fucoidan: an update. Mar Drugs 2015; 13 (9): 5920–5946.Fitton J.H., Stringer D.N., Karpiniec S.S. Therapies from fucoidan: an update. Mar Drugs 2015; 13 (9): 5920–5946.Subhash V., Ho B. Inflammation and proliferation — a causal event of host response to Helicobacter pylori infection. Microbiol 2015; 161 (6): 1150–1160.Subhash V., Ho B. Inflammation and proliferation — a causal event of host response to Helicobacter pylori infection. Microbiol 2015; 161 (6): 1150–1160.Fitton J.H. Therapies from fucoidans: multifunctional marine polymers. Mar Drugs 2011; 9: 1731–1760.Fitton J.H. Therapies from fucoidans: multifunctional marine polymers. Mar Drugs 2011; 9: 1731–1760.Soares C.M., Malagoli B.G., Menezes G.B., Pinho V.,Souza D.G.,Teixeira M.M. et al. Antiadhesive activity of polysaccharide-rich fractions from Lithothamnion muelleri. Z Naturforsch C J Biosci 2012; 67 (7–8): 391–397.Soares C.M., Malagoli B.G., Menezes G.B., Pinho V.,Souza D.G.,Teixeira M.M. et al. Antiadhesive activity of polysaccharide-rich fractions from Lithothamnion muelleri. Z Naturforsch C J Biosci 2012; 67 (7–8): 391–397.Jin W.,Zhang W., Liang H., Zhang Q. The structure — activity relationship between marine algae polysaccharides and anti-complement activity. Mar Drugs 2016; 14 (1): 3.Jin W.,Zhang W., Liang H., Zhang Q. The structure — activity relation-ship between marine algae polysaccharides and anti-complement activity. Mar Drugs 2016; 14 (1): 3.Manlusoc J.K.T., Hsieh C.L., Hsieh C.Y., Salac E.S.N., Lee Y.T., Tsai P.W. Pharmacologic application potentials of sulfated polysaccharide from marine algae. Polymers 2019; 11: 1163–1184.Manlusoc J.K.T., Hsieh C.L., Hsieh C.Y., Salac E.S.N., Lee Y.T., Tsai P.W. Pharmacologic application potentials of sulfated polysaccharide from marine algae. Polymers 2019; 11: 1163–1184.Park H.Y., Han M.H., Park C., Jin C.Y., Kim G.Y., Choi I.W. et al. Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol 2011; 49: 1745–1752.Park H.Y., Han M.H., Park C., Jin C.Y., Kim G.Y., Choi I.W. et al. Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol 2011; 49: 1745–1752.Wu G.J., Shiu S.M., Hsieh M.C., Tsai G.J. Anti-inflammatory activity of a sulfated polysaccharide from the brown alga Sargassum cristaefolium. Food Hydrocoll 2016; 53: 16–23.Wu G.J., Shiu S.M., Hsieh M.C., Tsai G.J. Anti-inflammatory activity of a sulfated polysaccharide from the brown alga Sargassum cristaefolium. Food Hydrocoll 2016; 53: 16–23.Sanjeeva K.K.A., Fernando I.P.S., Kim S.Y., Kim W. S., Ahn G., Jee Y. et al. Ecklonia cava (Laminariales) and Sargassum horneri (Fucales) synergistically inhibit the lipopolysaccharide-induced inflammation via blocking NF-kB and MAPK pathways. Algae 2019; 34 (1): 45–56.Sanjeeva K.K.A., Fernando I.P.S., Kim S.Y., Kim W. S., Ahn G., Jee Y. et al. Ecklonia cava (Laminariales) and Sargassum horneri (Fucales) synergistically inhibit the lipopolysaccharide-induced inflammation via blocking NF-kB and MAPK pathways. Algae 2019; 34 (1): 45–56.Saraswaty, Giriwono P.E., Iskandriati D.,Tan C.P., Andarwulan N. Sargassum seaweed as a source of anti-inflammatory substances and the potential insight of the tropical species: a review. Mar. Drugs 2019; 17 (10): 590.Saraswaty, Giriwono P.E., Iskandriati D.,Tan C.P., Andarwulan N. Sargassum seaweed as a source of anti-inflammatory substances and the potential insight of the tropical species: a review. Mar. Drugs 2019; 17 (10): 590.Matsumoto S., Nagaoka M., Hara T., Kimura-Takagi I., Mistuyama K., Ueyama S. Fucoidan derived from Cladosiphon okamuranus Tokida ameliorates murine chronic colitis through down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol 2004; 136 (3): 432–439.Matsumoto S., Nagaoka M., Hara T., Kimura-Takagi I., Mistuyama K., Ueyama S. Fucoidan derived from Cladosiphon okamuranus Tokida ameliorates murine chronic colitis through down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol 2004; 136 (3): 432–439.Никитина Л.В. Коррекция иммунных нарушений у детей с хроническим гастродуоденитом, ассоциированным с Helicobacter pylori. : автореф. днс. канд. мед. наук: Курск, 2012. - 18 с.Nikitina L.V. Korrektsiya immunnykh narushenij u detej s khronicheskim gastroduodenitom, assotsiirovannym s Helicobacter pylori.: avtoref. dis. kand. med. nauk: Kursk, 2012; 18. [in Russian]Kuznetsova T.A., Besednova N.N., Somova L.M., Plekhova N.G. Fucoidan Extracted from Fucus evanescens Prevents Endotoxin-Induced Damage in a Mouse Model of Endotoxemia. Mar Drugs 2014; 12 (2): 886–898.Kuznetsova T.A., Besednova N.N., Somova L.M., Plekhova N.G. Fucoidan Extracted from Fucus evanescens Prevents Endotoxin-Induced Damage in a Mouse Model of Endotoxemia. Mar Drugs 2014; 12 (2): 886–898.Butcher L.D., den Hartog G., Ernst P.B., Crowe S.E. Oxidative stress resulting from Helicobacter pylori infection contributes to gastric carcinogenesis. Cell Mol Gastroenterol Hepatol 2017; 3 (3): 316–322.Butcher L.D., den Hartog G., Ernst P.B., Crowe S.E. Oxidative stress resulting from Helicobacter pylori infection contributes to gastric carcinogenesis. Cell Mol Gastroenterol Hepatol 2017; 3 (3): 316–322.Байдик О.Д., Титаренко M.A., Сысолятин П.Г. Роль оксида азота (11) и его активных метаболитов в канцерогенезе полости рта. Российский стоматол журн. - 2016. - Т. 20. - № 3. - С. 165-168.Bajdik O.D., Titarenko M.A., Sysolyatin P.G. Rol' oksida azota (II) i ego aktivnykh metabolitov v kantserogeneze polosti rta. Rossijskij stomatol zhurn 2016;20 (3): 165–168. [in Russian]Ajisaka K., Yokoyama T., Matsuo K. Structural Characteristics and antioxidant activities from five brown seaweed. J of Applied Glycoscience 2016; 63 (2): 31–37.Ajisaka K., Yokoyama T., Matsuo K. Structural Characteristics and antioxidant activities from five brown seaweed. J of Applied Glycoscience 2016; 63 (2): 31–37.Xu S-Y., Huang X., Cheong K-L. Recent advances in marine algae polysaccharides: isolation, structure and activities. Mar Drugs 2017; 15 (12): 388.Xu S-Y., Huang X., Cheong K-L. Recent advances in marine algae polysaccharides: isolation, structure and activities. Mar Drugs 2017; 15 (12): 388.Tomori M., Nagamine T., Miyamoto T., Iha M. Evaluation of the immunomodulatory effects of fucoidan derived from Cladosiphon okamuranus Tokida in mice. Mar Drugs 2019; 17 (10): 547.Tomori M., Nagamine T., Miyamoto T., Iha M. Evaluation of the immunomodulatory effects of fucoidan derived from Cladosiphon okamuranus Tokida in mice. Mar Drugs 2019; 17 (10): 547.Asker M.S., El Kady E.M., Mahmoud M.G. New trends of the Polysaccharides as a drug. World J Agri Soil Sci 2019; 3 (4): 1–22.Asker M.S., El Kady E.M., Mahmoud M.G. New trends of the Polysaccharides as a drug. World J Agri Soil Sci 2019; 3 (4): 1–22.Lin Y.H., Lu K.Y., Tseng C.L., Wu J.Y., Chen C.H., Mi F.L. Development of genipin-crosslinked fucoidan/chitosan-N-arginine nanogels for preventing Helicobacter infection. Nanomedicine 2017; 12 (12): 1491-510.Lin Y.H., Lu K.Y., Tseng C.L., Wu J.Y., Chen C.H., Mi F.L. Development of genipin-crosslinked fucoidan/chitosan-N-arginine nanogels for preventing Helicobacter infection. Nanomedicine 2017; 12 (12): 1491-510.Gutiérrez-Zamorano C., González-Ávila M., Díaz-Blas G., Smith C.T., González-Correa C., García-Cancino A. Increased anti-Helicobacter pylori effect of the probiotic Lactobacillus fermentum UCO-979C strain encapsulated in gastric simulations under fasting conditions. Food Res Int 2019; 121: 812-816.Gutiérrez-Zamorano C., González-Ávila M., Díaz-Blas G., Smith C.T., González-Correa C., García-Cancino A. Increased anti-Helicobacter pylori effect of the probiotic Lactobacillus fermentum UCO-979C strain encapsulated in gastric simulations under fasting conditions. Food Res Int 2019; 121: 812-816.Pandey S., Kalvadia P., Patel H., Shah R., Gupta A., Shah D. Mucoadhesive microcapsules of amoxicillin trihydrate for effective treatment of H.pylori. Der Pharmacia Sinica 2014; 5 (2): 45–-55.Pandey S., Kalvadia P., Patel H., Shah R., Gupta A., Shah D. Mucoadhesive microcapsules of amoxicillin trihydrate for effective treatment of H.pylori. Der Pharmacia Sinica 2014; 5 (2): 45–-55.Arora S., Gupta S., Narang R.K., Budhiraja R.D. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H.pylori. Sci Pharm. 2011; 79 (3): 673–694.Arora S., Gupta S., Narang R.K., Budhiraja R.D. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H.pylori. Sci Pharm. 2011; 79 (3): 673–694.Adebisi A.O.,Conway B.R. Preparation and characterization of gastroretentive alginate beads for targeting H. pylori. J Microencapsul 2014; 31 (1): 58–67.Adebisi A.O.,Conway B.R. Preparation and characterization of gastroretentive alginate beads for targeting H.pylori. J Microencapsul 2014; 31 (1): 58–67.Аминина Н.М. Биологическая ценность морских водорослей дальневосточного побережья. Рыбпром: технологии и оборудование для переработки водных биоресурсов. - 2010. - № 3. - С. 32-35.Aminina N.M. Biologicheskaya tsennost' morskikh vodoroslej dal'nevostochnogo poberezh'ya. Rybprom: Tekhnologii i Oborudovanie dlya Pererabotki Vodnykh Bioresursov 2010; 3: 32–35. [In Russian]Abadi A.T.B. Vaccine against Helicobacter pylori: invitable approach. World J Gastroenterol 2016; 22 (11): 3150–3157.Abadi A.T.B. Vaccine against Helicobacter pylori: invitable approach. World J Gastroenterol 2016; 22 (11): 3150–3157.Pan X., Ke H., Niu X., Li S., Lv J., Pan L. Protection against Helicobacter pylori infection in Balb/c mouse model by oral administration of multi- valent epitope-based vaccine of cholera toxin B subunit-HUUC. Front Immunol 2018; 9: 1003.Pan X., Ke H., Niu X., Li S., Lv J., Pan L. Protection against Helicobacter pylori infection in Balb/c mouse model by oral administration of multivalent epitope-based vaccine of cholera toxin B subunit-HUUC. Front Immunol 2018; 9: 1003.Kuznetsova T.A., Persiyanova E.V., Ermakova S.P., Khotimchenko M.Y., Besednova N.N. The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants. Nat Prod Commun 2018; 13 (8): 1083–1095.Kuznetsova T.A., Persiyanova E.V., Ermakova S.P., Khotimchenko M.Y., Besednova N.N. The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants. Nat Prod Commun 2018; 13 (8): 1083–1095.Richter M.F., Hergenrother P.J. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics. Ann N Y Acad Sci 2019; 1435 (1): 18–38.Richter M.F., Hergenrother P.J. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics. Ann N Y Acad Sci 2019; 1435 (1): 18–38.Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature 2017; 543 (7643): 15.Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature 2017; 543 (7643): 15.

The authors declare that there are no conflicts of interest present.